Critical
Escitalopram × Methylthioninium chloride (methylene blue)
Selective serotonin reuptake inhibitors (SSRIs)×Antidotes (V03AB17). The drug has one FDA-approved indication – methaemoglobinaemia. Biohacker use is off-label.
Mechanism
IV methylene blue is a reversible MAO-A inhibitor. Escitalopram (SSRI) raises synaptic serotonin. Combined action sharply amplifies serotonergic transmission.
Symptoms
Serotonin syndrome: agitation, confusion, tremor, myoclonus, hyperreflexia, dilated pupils. Autonomic features: profuse sweating, tachycardia, hypertension, fever above 38.5 °C. Severe cases progress to seizures, rhabdomyolysis, disseminated intravascular coagulation, and death. First signs appear within hours of concurrent dosing.
Management
Avoid the combination. IV methylene blue is reserved for emergencies. For planned use, stop escitalopram 5 days in advance. On SSRI therapy, administer only for life-threatening indications under ICU monitoring.